1-2 of 2
Francesco Bosch
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL

Clinical Trials & Observations
Ian W. Flinn, Peter Hillmen, Marco Montillo, Zsolt Nagy, Árpád Illés, Gabriel Etienne, Julio Delgado, Bryone J. Kuss, Constantine S. Tam, Zoltán Gasztonyi, Fritz Offner, Scott Lunin, Francesco Bosch, Matthew S. Davids, Nicole Lamanna, Ulrich Jaeger, Paolo Ghia, Florence Cymbalista, Craig A. Portell, Alan P. Skarbnik, Amanda F. Cashen, David T. Weaver, Virginia M. Kelly, Barry Turnbull, Stephan Stilgenbauer
Journal: Blood
Blood (2018) 132 (23): 2446–2455.
https://doi.org/10.1182/blood-2018-05-850461
Published: 2018
Includes: Supplemental data
Journal Articles

Results from the Phase 3 DUO TM Trial: A Randomized Comparison of Duvelisib Vs Ofatumumab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Ian W. Flinn, MD PhD, Peter Hillmen, MBChB, PhD, Marco Montillo, MD, Zsolt Nagy, MD PhD, Árpád Illés, MD PhD, Gabriel Etienne, MD PhD, Julio Delgado, MD, Bryone Jean Kuss, PhDBMBS,FRCPA,FRACP, Constantine S. Tam, MBBS, MD FRACP, FRCPA, Zoltán Gasztonyi, MD, Fritz Offner, MD, Scott D Lunin, MD, Francesco Bosch, MD, Matthew S. Davids, MD MMSc, Nicole Lamanna, MD, Ulrich Jaeger, MD, Paolo Ghia, Florence Cymbalista, MD, Craig A. Portell, MD, Alan P Skarbnik, MD, Amanda Cashen, MD, Virginia Kelly, MD, Barry Turnbull, PhD, Stephan Stilgenbauer, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 493.
https://doi.org/10.1182/blood.V130.Suppl_1.493.493
Published: 2017